{
  "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac",
  "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 49,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Comparison of molecular weight (25 kDa vs 150 kDa) and administration method.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/21",
  "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac",
  "deckJsonHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac.json",
  "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.52,
        "y": 0.58
      },
      "kind": "callout",
      "text": "ALXN1720 demonstrated strong safety and tolerability profile in Phase I, initiating Phase III in gMG by YE2022",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f3b2d2c-083e-4f66-96cb-c2e5b72e2be5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.35,
        "x": 0.14,
        "y": 0.25
      },
      "kind": "image",
      "text": "Structural comparison of ALXN1720 and Soliris",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d3987db-f9a3-4711-b537-6b5103623b3f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.52,
        "y": 0.38
      },
      "kind": "list",
      "text": "Low molecular weight, QW self-admin auto-injector; Differentiated pricing expands indication opportunities; Potential best-in-class SC in gMG with potential to capture majority of self-admin market share",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85b571fe-9928-40a9-aca5-9c414c678984",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 1,
        "x": 0,
        "y": 0.85
      },
      "kind": "paragraph",
      "text": "ALXN1720, QW low-volume SC, supporting neurology expansion in gMG and DM",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a2b2e7d-6e95-45ba-a399-8cef2aff639a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.8,
        "x": 0.02,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "1. Direct to Phase III strategy. VHH Ab = single domain antibody; SC = subcutaneous; QW = once-weekly; self-admin = self-administered; gMG = generalised myasthenia gravis; YE = year-end; DM = dermatomyositis.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79fca5e3-dc71-4870-9154-451a6f309714",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ALXN1720 supports further indication expansion",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33c813d1-3188-47bc-a758-b147857529ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "title",
      "text": "Third-generation C5 mini-body (VHH Ab), potential best-in-class SC administration",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d4eb017-dbe8-4281-8442-c8bc3754b7c4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "f32e692e-1c26-4362-a310-ab10083d9331",
      "evidence": "Significant market expansion underway, demonstrated rapid conversion upon launch",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 29,
      "from": 20,
      "beatId": "c770ee9a-756c-43b6-a68c-b1bacde19cb7",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document provides data and evidence to support the effectiveness of AstraZeneca's medicines",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 29,
      "from": 20,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "4a5c4464-72f0-460e-8bff-ebe93fab6142",
      "evidence": "The document highlights the potential for quick wins and big bets in the rare disease space",
      "position": 2,
      "objective": "What are the key opportunities for AstraZeneca's Rare Disease division",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}